Rosetta Stone (NYSE:RST) Downgraded by ValuEngine

Share on StockTwits

ValuEngine cut shares of Rosetta Stone (NYSE:RST) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday, ValuEngine reports.

RST has been the topic of a number of other reports. Zacks Investment Research cut Rosetta Stone from a buy rating to a hold rating in a report on Saturday, November 2nd. Barrington Research reissued a buy rating and set a $29.00 price target on shares of Rosetta Stone in a report on Wednesday, August 7th.

NYSE RST traded down $0.62 on Wednesday, hitting $14.76. 358,914 shares of the company traded hands, compared to its average volume of 198,303. The company has a market capitalization of $498.69 million, a price-to-earnings ratio of -15.54 and a beta of 0.29. The business’s 50 day moving average price is $18.09 and its 200-day moving average price is $21.26. Rosetta Stone has a 52-week low of $13.76 and a 52-week high of $26.88.

Rosetta Stone (NYSE:RST) last released its earnings results on Wednesday, November 6th. The software maker reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.19. The company had revenue of $45.46 million for the quarter, compared to analysts’ expectations of $46.50 million. As a group, analysts anticipate that Rosetta Stone will post -0.6 EPS for the current year.

In other news, Director Laurence Franklin sold 10,181 shares of Rosetta Stone stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $19.69, for a total value of $200,463.89. Following the sale, the director now directly owns 38,057 shares of the company’s stock, valued at $749,342.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Nicholas C. Gaehde sold 2,500 shares of Rosetta Stone stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $20.00, for a total value of $50,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,782 shares of company stock worth $272,484. Insiders own 13.50% of the company’s stock.

Several hedge funds have recently modified their holdings of RST. Marshall Wace LLP bought a new stake in shares of Rosetta Stone in the first quarter worth about $34,000. Cortina Asset Management LLC increased its stake in Rosetta Stone by 11.5% during the second quarter. Cortina Asset Management LLC now owns 249,052 shares of the software maker’s stock worth $5,698,000 after acquiring an additional 25,591 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Rosetta Stone during the second quarter worth $203,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Rosetta Stone by 794.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,431 shares of the software maker’s stock worth $216,000 after purchasing an additional 8,377 shares in the last quarter. Finally, Aperio Group LLC acquired a new position in shares of Rosetta Stone during the second quarter worth $82,000. 86.45% of the stock is currently owned by hedge funds and other institutional investors.

Rosetta Stone Company Profile

Rosetta Stone Inc, together with its subsidiaries, provides technology-based learning products in the United States and internationally. It operates through three segments: Literacy, E&E Language, and Consumer Language. The company develops, markets, and supports a suite of language-learning, literacy, and brain fitness solutions consisting of Web-based software subscriptions, perpetual software products, online and professional services, audio practice products, and mobile applications.

Further Reading: Most Active Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Rosetta Stone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Stone and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.